GenesisCare signs MoU for Versa HD cancer treatment systems and research agreement with Elekta
Australia and Europe’s largest private provider of cancer care expands investment in Elekta’s innovative radiation therapy solutions and investigates potential to treat benign diseases
STOCKHOLM, November 14, 2018 – Elekta (EKTA-B.ST) announced today that GenesisCare has signed a Memorandum of Understanding (MoU) for Elekta Versa HD™ linear accelerators (linacs) to deliver radiation therapy across its growing network of oncology centers in Australia, the UK, Spain, and soon in China and South East Asia. It is valued at approximately USD 60 million. The MoU includes provisions for Elekta’s MOSAIQ® oncology information system (OIS) and Monaco® treatment planning system
In a separate research agreement, GenesisCare and Elekta agreed on a number of exciting initiatives including specific research into the management of benign disease with low dose radiation therapy regimes.
In 2016, Elekta announced a partnership with GenesisCare where it invested USD 100 million in sophisticated and leading-edge Elekta technology, including Versa HD linacs and software. More recently, in August 2018, GenesisCare became one of Australia’s first oncology service providers to order an Elekta Unity, the world’s first high field magnetic resonance radiation therapy (MR/RT) system, to be installed in the first half of 2019.
Richard Hausmann, Elekta CEO, says: “I am very happy that GenesisCare continues to choose Elekta as it expands to bring advanced precise cancer care where it is required. This latest agreement with GenesisCare confirms that Elekta not only meets the high demands of our customers but also provides state-of-the-art treatment options for their patients. We are also excited about the research agreement with GenesisCare. Elekta believes collaboration is the key to innovation and we anticipate our joint work can result in a broader range of treatments and improved processes.”
GenesisCare CEO, Dan Collins, says: “Radiation therapy is a highly effective, yet underutilized, form of cancer treatment, so we are pleased to be increasing access to this targeted technology through this new order for Elekta Versa HD linear accelerators. Bringing new technology to areas of need helps us have the greatest impact on both the patient experience and the life outcomes of more people with cancer.”
The Versa HD linacs in this agreement will be delivered over seven years. This agreement is separate to those previously announced in 2016.
Elekta Unity is listed in the Australian Register of Therapeutic Goods and Medsafe New Zealand, has CE mark and is pending FDA 510(k) premarket clearance, but not available for commercial distribution or sale in the U.S.
# # #
For further information, please contact:
Oskar Bosson, Global EVP Corporate Communications and Investor Relations
Tel: +46 70 410 7180, e-mail: Oskar.Bosson@elekta.com
Time zone: CET: Central European Time
Gunilla Öhman, Head of Investor Relations (interim)
Tel: +46 70 763 8125, e-mail: firstname.lastname@example.org
Time zone: CET: Central European Time
This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 08:00 CET on November 14, 2018. (REGMAR)
Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,700 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com